ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
A market and risk assessment of 125 turmeric supplements available in Australia, Germany, India, UK, and USA.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Turmeric: A Comprehensive Review of Its Botany, Traditional Uses, Phytochemistry, and Mechanisms as a Functional Food.Nutrients · 2026Pooled it
- Herbal does not mean harmless: A case of turmeric-associated AGEP.JAAD case reports · 2026Article
- Beyond the Rhizome: Phytochemistry, Biological Activities, and Sustainable Utilization ofPharmaceuticals (Basel, Switzerland) · 2026Review
- Translational Feasibility of Curcumin for Treatment of Alzheimer's Disease: A Critical Appraisal of Clinical Challenges.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Historically prominent in Ayurvedic cultures, turmeric (Curcuma longa), or "Haldi," is renowned for its anti-inflammatory and antioxidant effects, mainly due to its active compounds, curcuminoids. Due to the increasing use of turmeric supplements, this study critically examined 125 preparations across the UK, USA, India, Australia, and Germany and evaluated their compliance with evidence-based recommendations. Results reveal significant regulatory and labeling inconsistencies across countries, with 34% of preparations failing to disclose the active curcuminoid content. This lack of dosage regulation is especially concerning when considering the ongoing research into advanced delivery systems-such as nanoparticles, liposomes, micelles, and phospholipid complexes-which significantly enhance curcumin's absorption. Curcumin, a hydrophobic compound, undergoes rapid metabolism in the liver through Phase I and II detoxification pathways, particularly via cytochrome P450 enzymes and UDP-glucuronosyltransferase enzymes. This results in limited bioavailability, as curcumin is rapidly converted to water-soluble metabolites and excreted, reducing its effectiveness at therapeutic doses. However, through modern formulation technologies, curcumin can potentially not only alter drug metabolism, but its antioxidant action via Nrf2 activation can shift to pro-oxidant effects at high doses, causing oxidative stress and the accumulation of reactive metabolites. Emerging evidence suggests chronic low-dose use may lead to gastrointestinal, hepatic, or renal toxicity, yet turmeric preparations, falling within the scope of food law, lack the stringent controls applied to pharmaceuticals and are generally assumed safe. This study highlights the need for transparent labeling, clear dosage guidelines, and an understanding of curcumin's metabolic profile to guide consumers in maximizing benefits while mitigating risks. Furthermore, it aims to assist healthcare professionals in making informed recommendations regarding curcumin supplementation. Further research must include long-term clinical trials and potential standardization of curcumin supplement formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.